Hepatitis B virus infection: Epidemiology and vaccination

Epidemiologic Reviews

Volumn 28, Issue 1, 2006, Pages 112-125

  Shepard, Colin W ^a   Simard, Edgar P ^a   Finelli, Lyn ^a   Fiore, Anthony E ^a   Bell, Beth P ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Hepatitis B; Hepatitis B vaccines; Hepatitis B virus; Immunization programs

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATING DISEASE; DIABETES MELLITUS; DRUG ABUSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEVER; HEALTH CARE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE PAIN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SEROPREVALENCE; VIRUS INACTIVATION; VIRUS TRANSMISSION;

CHILD HEALTH SERVICES; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; HEALTH POLICY; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; SAFETY; WORLD HEALTH;

EID: 33747875872     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxj009     Document Type: Review

References (149)

1. Lurman A. Eine icterus epidemic. (In German). Berl Klin Woschenschr 1885;22:20-3.
2. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965;191:541-6.
3. Beasley P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
4. World Health Organization. Hepatitis B. (Fact sheet no. 204). Geneva, Switzerland: World Health Organization, 2000. (http://www.who.int/mediacentre/ factsheets/fs204/en/index. html).
5. World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec 2004;79:255-63.
6. Perz JF, Farrington LA, Armstrong GL, et al. Hepatocellular carcinoma and cirrhosis: global estimates of fractions attributable to viral hepatitis infection. (Abstract). Presented at "Hepatocellular Carcinoma: Screening, Diagnosis, and Management," a National Institutes of Health workshop, April 1-3, 2004. Bethesda, MD: National Institutes of Health, 2004.
7. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
8. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-9.
9. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000.
10. Krugman S, Overby LR, Mushahwar IK, et al. Viral hepatitis, type B: studies on natural history and prevention re-examined. N Engl J Med 1979;300:101-6.
11. Hoofnagle JH, DiBisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis 1991;11:73-83.
12. Ortiz-Interian CJ, de Medina MD, Perez GO, et al. Recurrence and clearance of hepatitis B surface antigenemia in a dialysis patient infected with the human immunodeficiency virus. Am J Kidney Dis 1990;16:154-6.
13. Davis CL, Gretch DR, Carithers RL Jr. Hepatitis B and transplantation. Infect Dis Clin North Am 1995;9:925-41.
14. Seeff LB, Beebe GW, Hoofnagle JH, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987;316:965-70.
15. Alward WL, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985;151:604-9.
16. Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991;13:627-31.
17. Adachi H, Kaneko S, Matsushita E, et al. Clearance of HBsAg in seven patients with chronic hepatitis B. Hepatology 1992;16:1334-7.
18. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-68.
19. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981;2:1129-33.
20. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae: prospective study of 1400 hepatitis B surface antigen-positive Alaska Native carriers. Arch Intern Med 1990;150:1051-4.
21. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41.
22. Bond WW, Petersen NJ, Favero MS. Viral hepatitis B: aspects of environmental control. Health Lab Sci 1977;14:235-52.
23. Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Lancet 1984;1:921-6.
24. Xu ZY, Liu CB, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-18.
25. Beasley RP, Trepo C, Stevens CE, et al. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105:94-8.
26. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1:889-93.
27. Armstrong GL, Mast EE, Wojczynski M, et al. Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics 2001;108:1123-8.
28. Mast EE, Mahoney F, Kane M, et al. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Philadelphia, PA: W B Saunders Company, 2004:299-337.
29. Francis DP, Favero MS, Maynard JE. Transmission of hepatitis B virus. Semin Liver Dis 1981;1:27-32.
30. Favero MS, Maynard JE, Petersen NJ, et al. Hepatitis-B antigen on environmental surfaces. (Letter). Lancet 1973;2:1455.
31. Lauer JL, VanDrunen NA, Washburn JW, et al. Transmission of hepatitis B virus in clinical laboratory areas. J Infect Dis 1979;140:513-16.
32. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990;74: 1529-41.
33. Heathcote J, Gateau PH, Sherlock S. Role of hepatitis-B antigen carriers in non-parenteral transmission of the hepatitis-B virus. Lancet 1974;2:370-2.
34. Alter MJ, Ahtone J, Weisfuse I, et al. Hepatitis B transmission between heterosexuals. JAMA 1986;256:1307-10.
35. Alter MJ, Coleman PJ, Alexander JW, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-5.
36. Dietzman DE, Harnisch JP, Ray CG, et al. Hepatitis B surface antigen (HBsAg) and antibody to HBsAg: prevalence in homosexual and heterosexual men. JAMA 1977;238:2625-6.
37. MacKellar DA, Valleroy LA, Secura GM, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001;91:965-71.
38. Levine OS, Vlahov D, Nelson KE. Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev 1994;16:418-36.
39. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.
40. Levine OS, Vlahov D, Koehler J, et al. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol 1995;142:331-41.
41. Limentani AE, Elliott LM, Noah ND, et al. An outbreak of hepatitis B from tattooing. Lancet 1979;2:86-8.
42. Kent GP, Brondum J, Keenlyside RA, et al. A large outbreak of acupuncture-associated hepatitis B. Am J Epidemiol 1988;127:591-8.
43. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR Morb Mortal Wkly Rep 1989;38(suppl 6):1-37.
44. Hadler SC, Doto IL, Maynard JE, et al. Occupational risk of hepatitis B infection in hospital workers. Infect Control 1985;6:24-31.
45. Beltrami EM, Williams IT, Shapiro CN, et al. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev 2000;13:385-407.
46. Hauri AM, Armstrong GL, Hutin YJF. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004;15:7-16.
47. Polish LB, Shapiro CN, Bauer F, et al. Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger-stick device. N Engl J Med 1992;326:721-5.
48. Samadari T, Malakmadze N, Balter S, et al. A large outbreak of hepatitis B virus infections associated with frequent injections at a physician's office. Infect Control Hospital Epidemiol 2005;26:745-50.
49. Transmission of hepatitis B virus among persons undergoing blood glucose monitoring in long-term-care facilities - Mississippi, North Carolina, and Los Angeles County, California, 2003-2004. MMWR Morb Mortal Wkly Rep 2005;54:220-3.
50. Williams IT, Perz JF, Bell BP. Viral hepatitis in ambulatory care settings. Clin Infect Dis 2004;38:1592-8.
51. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;50:1-43.
52. Gunson RN, Shouval D, Roggendorf M, et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003;27:213-30.
53. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003;289:959-63.
54. Lin HH, Kao JH, Chang TC, et al. Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. J Med Virol 2003;69:466-70.
55. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 1996;38(suppl 2):S39-42.
56. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38(suppl 3):S158-68.
57. Population Reference Bureau. 2005 world population data sheet of the Population Reference Bureau. Washington, DC: Population Reference Bureau, 2005. (http://www.prb.org/pdf05/05WorldDataSheet_Eng.pdf#search5'2005%20 world%20population%20data%20sheet').
58. Lin DB, Wang HM, Lee YL, et al. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine 1998;16:1683-7.
59. Sung JL, Chen DS, Lai MY, et al. Hepatitis B e antigen and antibody in asymptomatic Chinese with hepatitis B surface antigenemia in Taiwan. Gastroenterol Jpn 1982;17:341-6.
60. Whittle HC, Bradley AK, McLauchlan K, et al. Hepatitis B virus infection in two Gambian villages. Lancet 1983;1:1203-6.
61. Kurien T, Thyagarajan SP, Jeyaseelan L, et al. Community prevalence of hepatitis B infection and modes of transmission in Tamil Nadu, India. Indian J Med Res 2005;121:670-5.
62. Iashina TL, Favorov MO, Shakhgil'dian IV, et al. The prevalence of the markers of viral hepatitis B and delta among the population in regions differing in the level of morbidity. (In Russian). Vopr Virusol 1992;37:194-6.
63. Erden S, Buyukozturk S, Calangu S, et al. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. Med Princ Pract 2003;12:184-8.
64. Da Villa G, Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 1999;17:1734-8.
65. Brasil LM, da Fonseca JC, de Souza RB, et al. Prevalence of hepatitis B virus markers within household contacts in the State of Amazonas. Rev Soc Bras Med Trop 2003;36:565-70.
66. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18.
67. Franks AL, Berg CJ, Kane MA, et al. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. N Engl J Med 1989;321:1301-5.
68. Mahoney FJ, Lawrence M, Scott C, et al. Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. Pediatrics 1995;96:1113-16.
69. Schreeder MT, Bender TR, McMahon BJ, et al. Prevalence of hepatitis B in selected Alaskan Eskimo villages. Am J Epidemiol 1983;118:543-9.
70. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54:1-31.
71. Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990;8(suppl):S74-8.
72. Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
73. Shaw FE, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425-30.
74. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J 1993;12:438-45.
75. Marion SA, Pastore MT, Pi DW, et al. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994;140:734-46.
76. McMahon BJ, Helminiak C, Wainwright RB, et al. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992;92:254-6.
77. Niu MT, Rhodes P, Salive M, et al. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998;51:503-10.
78. Lewis E, Shinefield HR, Woodruff BA, et al. Safety of neonatal hepatitis B vaccine administration. Pediatr Infect Dis J 2001;20:1049-54.
79. Institute of Medicine Vaccine Safety Committee. Hepatitis B vaccines. In: Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington, DC: National Academies Press, 1994:211-35.
80. Niu MT, Salive ME, Ellenberg SS. Neonatal deaths after hepatitis B vaccine: the Vaccine Adverse Event Reporting System, 1991-1998. Arch Pediatr Adolesc Med 1999;153:1279-82.
81. Eriksen EM, Perlman JA, Miller A, et al. Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the Vaccine Safety Datalink Project. Pediatr Infect Dis J 2004;23:656-62.
82. DeStefano F, Mullooly JP, Okoro CA, et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 2001;108:E112. (Electronic article).
83. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003;60:504-9.
84. Institute of Medicine, Immunization Safety Review Committee. Stratton K, Almario DA, McCormick CM, eds. Immunization safety review: hepatitis B vaccine and demyelinating neurological disorders. Washington, DC: National Academies Press, 2002. (http://www.nap.edu/catalog/10393.html?onpi_newsdoc05302002).
85. Banatvala JE, Van Damme P. Hepatitis B vaccine - do we need boosters? J Viral Hepat 2003;10:1-6.
86. Dentiger CM, McMahon BJ, Fiore AE, et al. Anti-HBs persistence and response to a hepatitis B vaccine (HB) boost among Yup'ik Eskimos 22 years after HB vaccination. (Abstract 1028). In: Abstracts of the Infectious Diseases Society of America 43rd Annual Meeting, San Francisco, California, October 6 to 9, 2005. Alexandria, VA: Infectious Diseases Society of America, 2005.
87. Milne A, Waldon J. Recombinant DNA hepatitis B vaccination in teenagers: effect of a booster at 5 1/2 years. (Letter). J Infect Dis 1992;166:942.
88. Watson B, West DJ, Chilkatowsky A, et al. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001;19:3164-8.
89. Williams IT, Goldstein ST, Tufa J, et al. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003;22:157-63.
90. Zanetti AR, Mariano A, Romano L, et al. Long term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366:1379-84.
91. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004;23:650-5.
92. Samandari T, Fiore A, McMahon B, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. (Abstract 1029). In: 43rd Annual Meeting of IDSA, October 6-9, 2005 - San Francisco. Alexandria, VA: Infectious Diseases Society of America, 2005:226. (http://www.idsociety.org/ Content/ContentGroups/ Annual_Meeting1/2005/Final_ Program/Poster_Abstracts_last.pdf).
93. Hsu HY, Chang MH, Liaw SH, et al. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999;30:1312-17.
94. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;4(suppl 1):11-20.
95. Ngui SL, O'Connell S, Eglin RP, et al. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 1997;176:1360-5.
96. Nainan OV, Khristova ML, Byun K, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002;68:319-27.
97. Ogata N, Cote PJ, Zanetti AR, et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999;30:779-86.
98. Hussain M, Chu CJ, Sablon E, et al. Rapid and sensitive detection assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003;41:3699-705.
99. World Health Organization. Hepatitis B vaccine. Geneva, Switzerland: World Health Organization, 2005. (http://www.who.int/vaccines/en/hepatitisb. shtml/shtml#strategies).
100. World Health Organization. 2004 global immunization data. Geneva, Switzerland: World Health Organization, 2005. (http://www.who.int/ immunization_monitoring/data/GlobalImmunizationData.pdf).
101. Kane MA. Status of hepatitis B immunization programmes in 1998. Vaccine 1998;16(suppl):S104-8.
102. World Health Organization. WHO-UNICEF estimates of HepB3 coverage. Geneva, Switzerland: World Health Organization, 2005. (http://www.who.int/ immunization_monitoring/en/globalsummary/timeseries/tswucoveragehepb3.htm).
103. Global Alliance for Vaccines and Immunization. General principles for use of GAVI/Vaccine Fund resources in phase 2. Geneva, Switzerland: Global Alliance for Vaccines and Immunization, 2005. (http://www.vaccinealliance.org/ General_Information/About_alliance/Principles.php).
104. World Health Organization. Global and regional immunization profile. In: WHO vaccine-preventable disease monitoring system, 2005 global summary. Geneva, Switzerland: World Health Organization, 2005. (http://www.who.int/ immunization_monitoring/en/globalsummary/gs_gloprofile. pdf).
105. Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. MMWR Morb Mortal Wkly Rep 1988;37:341-6, 351.
106. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40:1-25.
107. Update: recommendations to prevent hepatitis B virus transmission - United States. MMWR Morb Mortal Wkly Rep 1995;44:574-5.
108. Update: recommendations to prevent hepatitis B virus transmission - United States. MMWR Morb Mortal Wkly Rep 1999;48:33-4.
109. National, state, and urban area vaccination coverage among children aged 19-35 months - United States, 2004. MMWR Morb Mortal Wkly Rep 2005;54:717-21.
110. Hepatitis B vaccination - United States, 1982-2002.MMWR Morb Mortal Wkly Rep 2002;51:549-552, 563.
111. Yusuf HR, Daniels D, Mast EE, et al. Hepatitis B vaccination coverage among United States children. Pediatr Infect Dis J 2001;20:830-3.
112. Effectiveness of a middle school vaccination law - California, 1999-2001. MMWR Morb Mortal Wkly Rep 2001;50:660-3.
113. Immunization Action Coalition. Hepatitis B prevention mandates. St. Paul, MN: Immunization Action Coalition, 2004. (http://www.immunize.org/laws/hepb. htm).
114. Schrag SJ, Arnold KE, Mohle-Boetani JC, et al. Prenatal screening for infectious diseases and opportunities for prevention. Obstet Gynecol 2003;102:753-60.
115. Program to prevent perinatal hepatitis B virus transmission in a health-maintenance organization - Northern California, 1990-1995. MMWR Morb Mortal Wkly Rep 1997;46:378-80.
116. Kohn M, Farley T, Scott C. The need for more aggressive follow-up of children born to hepatitis B surface antigen-positive mothers: lessons from the Louisiana Perinatal Hepatitis B Immunization Program. Pediatr Infect Dis J 1996;15:535-40.
117. Hepatitis B vaccine coverage among adults - United States, 2004. MMWR Morb Mortal Wkly Rep 2006;55:509-11.
118. Simard EP, Miller JT, George PA, et al. Hepatitis B vaccination coverage levels among health care workers in the United States, 2002-2003. (Abstract 1030). In: Abstracts of the Infectious Diseases Society of America 43rd Annual Meeting, San Francisco, California, October 6 to 9, 2005. Alexandria, VA: Infectious Diseases Society of America, 2005.
119. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005;18:52-61.
120. Jain N, Yusuf H, Wortley PM, et al. Factors associated with receiving hepatitis B vaccination among high-risk adults in the United States: an analysis of the National Health Interview Survey, 2000. Fam Med 2004;36:480-6.
121. Hepatitis B vaccination among high-risk adolescents and adults - San Diego, California, 1998-2001. MMWR Morb Mortal Wkly Rep 2002;51:618-21.
122. Weinberg MS, Gunn RA, Mast EE, et al. Preventing transmission of hepatitis B virus from people with chronic infection. Am J Prev Med 2001;20:272-6.
123. Chan CY, Lee SD, Lo KJ. Legend of hepatitis B vaccination: the Taiwan experience. J Gastroenterol Hepatol 2004;19:121-6.
124. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
125. Lee CL, Hsieh KS, Ko YC. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 2003;12:57-9.
126. Kao JH, Hsu HM, Shau WY, et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-52.
127. Viviani S, Jack A, Hall AJ, et al. Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine 1999;17:2946-50.
128. Chotard J, Inskip HM, Hall AJ, et al. The Gambia Hepatitis Intervention Study: follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis 1992;166:764-8.
129. Bhimma R, Coovadia HM, Adhikari M, et al. The impact of hepatitis B vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. Arch Pediatr Adolesc Med 2003;157:1025-30.
130. Ng KP, Saw TL, Baki A, et al. Impact of expanded program of immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol 2005;194:163-8.
131. Bonanni P, Pesavento G, Bechini A, et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003;21:685-91.
132. Namgyal P. Impact of hepatitis B immunization, Europe and worldwide. J Hepatol 2003;39(suppl 1):S77-82.
133. Harpaz R, McMahon BJ, Margolis HS, et al. Elimination of new chronic hepatitis B infections: results of the Alaska immunization program. J Infect Dis 2000;181:413-18.
134. Fiore A, Neeman R, Lee S, et al. Seroprevalence of hepatitis B virus (HBV) infection among Asian immigrants and their US-born children in Georgia. (Abstract 586). In: Abstracts of the Infectious Diseases Society of America 41st Annual Meeting, San Diego, California, October 9 to 12, 2003. Alexandria, VA: Infectious Diseases Society of America, 2003.
135. Centers for Disease Control and Prevention. Hepatitis surveillance report no. 61. Atlanta, GA: Centers for Disease Control and Prevention (in press).
136. Acute hepatitis B among children and adolescents - United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2004;53:1015-18.
137. Euler GL, Wooten KG, Baughman AL, et al. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. Pediatrics 2003;111:1192-7.
138. Thomas AR, Fiore AE, Corwith HL, et al. Hepatitis B vaccine coverage among infants born to women without prenatal screening for hepatitis B virus infection: effects of the Joint Statement on Thimerosal in Vaccines. Pediatr Infect Dis J 2004;23:313-18.
139. Luman ET, Fiore AE, Strine TW, et al. Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage. JAMA 2004;291:2351-8.
140. Euler GL, Copeland J, Williams WW. Impact of four urban perinatal hepatitis B prevention programs on screening and vaccination of infants and household members. Am J Epidemiol 2003;157:747-53.
141. Roome A, Rak M, Hadler J. Follow-up of infants of hepatitis B-infected women after hepatitis B vaccination, Connecticut, 1994 to 1997. Pediatr Infect Dis J 2000;19:573-4.
142. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Provisional recommendations for hepatitis B vaccination of adults. Atlanta, GA: Centers for Disease Control and Prevention, 2005. (http://www.cdc.gov/nip/recs/provisional_recs/hepB_adult.pdf).
143. Khan A, Goldstein S, Williams I, et al. Opportunities for hepatitis B prevention in correctional facilities and sexually transmitted disease treatment settings. (Abstract 37). In: Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease, 2000 April 9-13, Atlanta, GA. Atlanta, GA: International Medical Press, 2002.
144. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States 1982-1998: implications for vaccination programs. J Infect Dis 2002;185:713-19.
145. Williams IT, Boaz K, Openo KP, et al. Missed opportunities for hepatitis B vaccination in correctional settings, sexually transmitted disease (STD) clinics, and drug treatment programs. (Abstract 1031). In: Abstracts of the Infectious Diseases Society of America 43rd Annual Meeting, San Francisco, California, October 6 to 9, 2005. Alexandria, VA: Infectious Diseases Society of America, 2005.
146. Samoff E, Dunn A, Vandevanter N, et al. Predictors of acceptance of hepatitis B vaccination in an urban sexually transmitted diseases clinic. Sex Transm Dis 2004;31:415-20.
147. Rudy ET, Detels R, Douglas W, et al. Factors affecting hepatitis vaccination refusal at a sexually transmitted disease clinic among men who have sex with men. Sex Transm Dis 2003;30:411-18.
148. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep 2003;52:1-36.
149. Hepatitis B vaccination for injection drug users - Pierce County, Washington, 2000. MMWR Morb Mortal Wkly Rep 2001;50:388-90, 399.